NRXN3 and Alzheimer disease: The GEO verification results showed that nrxn3 expression in TB patients decreased after chemotherapy, but current studies have shown that rifampicin can have therapeutic effects on AD through anti-inflammatory, anti-tau, anti-amyloid, and cholinergic effects (Yulug et al., 2018).